Falchi-Carvalho M

Advanced Research Center with Psychedelics, Federal University of Rio Grande do Norte, Natal, RN, Brazil; Department of Clinical Medicine, Federal University of Rio Grande do Norte, Natal, RN, Brazil.

14 papers · 3 preprints · ORCID

ArticleKetamine

Exploratory non-randomized clinical trial of subcutaneous esketamine in treatment-resistant depression: Effects of ketamine-assisted psychotherapy.

Varela YM, Cavalcanti-Ribeiro P, de Sousa GM +18

Europe PMC2026
ArticleKetamine

Dissociation and antidepressant response to subcutaneous esketamine: A clinical study.

Gonçalves KTDC, Tavares VDO, Palhano-Fontes F +12

Europe PMC2026
ArticleDMT

Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression.

Bolcont R, Palhano-Fontes F, Barros H +6

Europe PMC2026
PreprintKetamine

Preliminary Non-Randomized Clinical Trial of Subcutaneous Esketamine in Treatment-Resistant Depression: Exploring Adjunctive Effects of Ketamine-Assisted Psychotherapy

Varela YM, Cavalcanti-Ribeiro P, de Sousa GM +18

Europe PMC2026
PreprintDMT

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality

Wießner I, Falchi-Carvalho M, Laborde S +7

Europe PMC2026
ArticleDMT

Corrigendum to Safety, tolerability and subjective effects of vaporized N, N-Dimethyltryptamine: A randomized double-blind clinical trial [European Neuropsychopharmacology 97 (2025) 16-27].

Wießner I, Falchi-Carvalho M, Laborde S +18

Europe PMC2026
ArticlePsilocybin

Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics.

Varela YM, de O Tavares VD, Delgado LM +12

Europe PMC2026
ArticleKetamine

Inflammatory response to repeated subcutaneous esketamine in treatment-resistant depression: The role of baseline C-reactive protein.

Cavalcanti-Ribeiro P, De Souza LCAM, de Tavares VDO +11

Europe PMC2026
ArticleDMT

Expressive resource in a clinical psychedelic study: Art as an integration tool.

Barros H, Falchi-Carvalho M, Maia LO +5

Europe PMC2025
ArticleDMT

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.

Wießner I, Falchi-Carvalho M, Laborde S +18

Europe PMC2025
ArticlePsilocybin

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.

Falchi-Carvalho M, Palhano-Fontes F, Wießner I +21

Europe PMC2025
ArticleAyahuasca

The Antidepressant Effects of Vaporized <i>N</i>,<i>N</i>-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression.

Falchi-Carvalho M, Barros H, Bolcont R +16

Europe PMC2025
ArticleKetamine

Ketamine's Altered States Meta-Analysis: The Relationship Between Psychomimetic and Clinical Effects With Focus in Depression.

Tavares VDO, da Costa Gonçalves KT, de Morais Barros ML +10

Europe PMC2025
ArticleKetamine

Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.

da Costa Gonçalves KT, de Tavares VDO, de Morais Barros ML +9

Europe PMC2025
ArticleKetamine

Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study.

Palhano-Fontes F, Cavalcanti-Ribeiro P, da Costa Gonçalves KT +13

Europe PMC2025
PreprintAyahuasca

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

Falchi-Carvalho M, Barros H, Bolcont R +15

Europe PMC2024
ArticlePsilocybin

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.

Falchi-Carvalho M, Wießner I, Silva SRB +15

Europe PMC2024